DeSci is ripping up the rulebook for bio. By throwing open the doors to scientific knowledge and harnessing the power of open-source, it’s unleashing a tidal wave of credible new approaches and collaborations. The result? A total disruption of the typical go-to-market model for the drug development and biotech industry.
The problem: Pharma’s ROI on R&D is in freefall. Skyrocketing costs, snail-pace development, and sky-high abandonment rates, leaving many potential breakthroughs unrealised.